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Abstract
The Atlas human cDNA expression array was used to
evaluate gene expression profile changes in the genesis
of human lung adenocarcinomas and squamous cell
carcinomas. Gene expression changes between adeno-
carcinomas and squamous cell carcinomas were also
analyzed. Of the 588 gene targets, 262 genes were
expressed in these tissues and, of these, 45 genes were
differentially expressed by at least two-fold in tumor
tissues compared to corresponding normal tissues.
Semiquantitative reverse - transcriptase polymerase
chain reaction was used to confirm gene expression
changes. Only those genes that reflected changes in
>50% of the analyzed tissues were included in the final
analysis. Ultimately, 26 genes were evaluated with 14
genes overexpressed and 12 genes underexpressed
compared to matching normal lung tissues. Although
similar expression changes were detected in adenocar-
cinomas and squamous cell carcinomas for most of the
genes analyzed, some subtype-specific differences
were also found. Genes encoding cell cycle regulators,
intracellular signal transducers, cell receptor and adhe-
sion molecules, growth factors, oncogenes, and apop-
totic effectors were differentially expressed in this
study. These gene expression changes may directly
contribute to the initiation or progression of human lung
cancer or may be secondary effects of the tumori-
genesis process. Regardless, many of these differences
may be useful in the diagnosis and/or treatment of this
deadly disease.
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Introduction
An estimated 553,400 Americans will lose their lives to
cancer in the year 2001. Lung cancer is the most common
type of cancer death among men and women in the United
States, with an estimated 169,500 new cases and 157,400
deaths predicted for the year 2001 [1]. The molecular
pathogenesis of human cancer involves the accumulation
of genetic and epigenetic alterations in cancer- related
genes [2,3]. Progression to lung cancer is believed to
involve 10 to 20 alterations, including the activation of
proto-oncogenes and the inactivation of tumor suppressor
genes [4]. In addition to overriding growth control mecha-
nisms, transformed cells must also avoid programmed cell
death that can ensue when cell cycle checkpoint control is
lost. Although most tumors have high rates of apoptotic
death, cancer cells frequently inactivate components of
apoptotic pathways and induce cell survival genes [5].
Additional alterations may include disruption of DNA repair
genes and chromosomal fragile sites as well as activation of
invasive, metastatic, and/or angiogenic factors. Genetic
susceptibility may also contribute to the development of
human lung cancer [4,6 ].
Lung cancers are broadly categorized into two histologic
groups. Small cell lung cancer (SCLC) is diagnosed in
approximately 20% to 25% of all lung cancer cases and
non–small cell lung cancer (NSCLC) is diagnosed in the
remaining 75% to 80% of cases [7,8]. NSCLC is further
subdivided into three groups: 1) squamous cell carcinoma
is characterized by rapidly growing epidermoid cells that
produce keratin (25%); 2) adenocarcinoma arises periph-
erally and is composed of cuboidal or columnar cells that
can form glandular patterns and produce mucin (30%); 3)
large cell carcinoma consists of a heterogeneous mix of
poorly differentiated cells that do not resemble cells from
the other two categories (10%) [7,8 ].
Cytogenetic and molecular studies have revealed different
genetic alterations in these two histologic subgroups. For
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example, the expression frequency of Bcl -2 is much higher
in SCLC (75% to 95%) than in NSCLC (10% to 35%) [6,9-
11]. Additionally, within NSCLC, squamous cell carcinomas
express higher levels of Bcl-2 more frequently than
adenocarcinomas (25% to 35% vs. 10%, respectively)
[6,10,12,13]. Abnormal Rb protein expression is detected in
over 90% of SCLC but only 15% to 30% of NSCLC [14-16].
p16INK4a inactivation is more frequently detected in NSCLC
(10% to 40%) and very rarely in SCLC ( <1%) [6,17,18].
Activating point mutations in the ras gene family occur in
20% to 30% of adenocarcinomas and 15% to 20% of all
NSCLC but in <1% of SCLC [6,19]. In contrast, the
frequency of abnormal p53 expression detected by immu-
nohistochemistry is 40% to 70% for both SCLC and
NSCLC [20-22]. Most studies have reported a higher
frequency of abnormal expression of the p53 gene in
squamous cell carcinomas compared to adenocarcinomas
[6]. In SCLC, losses from chromosomes 1p, 3p, 5q, 17p, and
10q predominate [23,24]. Common alterations in NSCLC
include 3p, 6q, 8p, 9p, 9q, 13q, 17p, 18q, 19p, 21q, 22q, as
well as +7, i(5)(p10) and i(8)(q10) [23,25]. Genetic
alterations appear to differ between SCLC and NSCLC and
possibly even between NSCLC subtypes.
Using a human cDNA expression array, we determined
gene expression profile changes between human lung
NSCLCs and normal human lung tissues. We also analyzed
the gene expression profile changes between human lung
squamous cell carcinomas and adenocarcinomas with
respect to their matching normal lung tissues. The cDNA
expression arrays allow for rapid, high-throughput analyses
of gene expression patterns in tissues. Analysis of differ-
entially expressed genes in human lung tumors may reveal
additional, unsuspected genes involved in lung tumori-
genesis, provide novel diagnostic markers or chemopreven-
tive targets, and/or implicate the involvement of other
molecular pathways in cancer development.
Materials and Methods
Tissue Specimens
Frozen lung cancer specimens and matching normal
tissues were obtained from Cooperative Human Tissue
Network through The Ohio State University Department of
Pathology. Fourteen pairs of clinical samples (seven
squamous cell carcinomas with their normal controls and
seven adenocarcinomas with their normal controls) were
used in this study (Table 1). Frozen tumor tissues were
microdissected to determine the tumor versus normal cell
ratio for each specimen. Tissues were embedded in Tissue
Tek OCT compound (VWR Scientific Products, West
Chester, PA), cryostat sectioned, and stained with hemo-
toxin and eosin for microscopy. Tumor tissue sections
corresponding to the microscopic sections containing
70% tumor cells were isolated and stored at 808C for
subsequent RNA isolation. Matching normal tissues were
also microdissected to ensure that specimens consisted of
purely normal lung tissue. Figure 1 shows the typical
Table 1. Description of Adenocarcinomas and Squamous Cell Carcinomas Used in This Study.
Patient No. Description Location Diagnosis Other Relevant Facts
8322 48Y, W, F RLL Invasive, moderately differentiated SCC Smoker: 1 ppd25 years; prior SCC of the lung treated with radiation;
mother died of breast cancer
8326 72Y, W, F RLL Moderately differentiated SSC; vascular
invasion; lymph node metastasis
Smoker: 1 / 2 ppd30 years; prior SCC of the lung treated with
chemotherapy5
8599 62Y, F RA Lung Moderately to poorly differentiated SCC; pleural
and intrapulmonary lymphatic invasion
Prior right lung cancer
8611 67Y, M LUL Moderately differentiated bronchogenic
SSC with desmoplastic reaction
Atelectasis and inflammation with cavitation and hemorrhage
8706 74Y, M LUL Poorly differentiated SSC with extensive necrosis Emphysematous change with focal chronic interstitial pneumonitis
and fibrosis; atelectasis
94 -10 -A039 68Y, W, M RUL Moderately differentiated SCC with no
evidence of keratin formation;
adenosquamous in some areas
Moderate emphysema in normal lung tissue
94 -11 -A120 58Y, W, M LLL Poorly differentiated endobronchial SSC with
lymph node metastasis
Prior asbestos exposure
5796 69Y, F RUL Moderately to poorly differentiated alveolar AdC
with extensive central necrosis
Moderate lymphocytic host response
8252 70Y, W, F RML Poorly differentiated AdC with bronchioalveolar
pattern at its periphery; lymph node metastasis
Prior cervical carcinoma but compatible with primary lung carcinoma
8606 52Y, W, F LLL Poorly differentiated AdC with lymph node
metastasis
Smoker: 1.5 ppd32 years; prior RU lobe tumor; post - obstructive
chronic pneumonia
8607 45Y, W, F LUL;
LLL
Adenocarcinoma; mass present at hilum and
junction of LU lobe and LL lobe
Brain metastasis
8641 68Y, B, F RML Moderately differentiated AdC invading into
bronchus and vasculature
Tumor destroys and fills one bronchus; chronic bronchitis and
centrilobular emphysema
8712 76Y, W, F RUL Moderately differentiated AdC with lymph
node metastasis
History of skin cancer and primary RU lobe lung cancer
94 -11 -C066 51Y, M RLL Poorly differentiated AdC Smoker: 1.5 ppd30 years
Abbreviations: AdC, adenocarcinoma. SCC, squamous cell carcinoma. W, white. B, black. F, female. M, male. Y, years old. ppd, packs per day.
Location: first position: R, right; L, left; second position: U, upper; M, middle; L, lower; third position: L, lobe.
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morphology of normal alveoli and an adenocarcinoma as
well as a normal bronchiole and a squamous cell carcinoma
used in this study.
PolyA+ RNA Isolation
Total RNAwas extracted using TRI-Reagent according to
standard protocol (Molecular Research Center, Cincinnati,
OH). Briefly, after homogenization in 5.0 ml TRI-Reagent,
1.0 ml chloroform was added per sample, shaken vigorously,
and centrifuged for 15 minutes at 48C, 12,000g. The clear,
upper phase containing total RNA was collected for isolation
of the polyA+ RNA fraction. One volume of aqueous phase
was mixed with 0.1 volume of 1 M Tris ( free base) and 0.8
volume isopropanol and stored at room temperature for
approximately 5 minutes. Meanwhile, oligo(dT)-cellulose
columns (Molecular Research Center ) were washed with 1.0
ml binding buffer (0.5 M LiCl, 50 mM sodium citrate, 0.1%
SDS). The RNA suspension was applied to the cellulose
column to which the polyA+ RNA adheres. The columns
were then washed with 0.5 ml 75% ethanol and 1.0 ml
binding buffer. Finally, the polyA+ RNA fraction was eluted
from the column with 0.6 ml elution buffer (1 mM sodium
citrate, 0.1% SDS), quantitated by spectrophotometry, and
precipitated with a final concentration of 0.3 M NaCl and 1.5
volumes isopropanol. Pellets were dissolved in nuclease-
free water to a final concentration of 1 g/L.
cDNA Expression Array Hybridization
A total of 5 g of polyA+ RNA was reverse transcribed
using 0.2CDSprimermix (Clontech Laboratories, PaloAlto,
CA); 10 mM DTT; 1 reverse transcription buffer (50 mM
Tris–HCl, pH 8.3; 75 mM KCl; 3 mM MgCl2); 1 mM each of
dATP, dTTP, and dGTP; 80 U RNAsin (Promega, Madison,
WI); 50 Ci [ - 32P]dCTP and 800 units MMLV reverse
transcriptase (Gibco BRL Life Technologies, Carlsbad, CA).
Themixturewas incubatedat 378Cfor 1hourand thenpurified
by centrifugation throughG50Sephadex columns, denatured
at 958C for 10 minutes, and hybridized to Atlas cDNA
Figure 1. Histology of normal and tumor tissues used in this study.
Neoplasia . Vol. 4, No. 2, 2002
Gene Expression in Non-small Cell Lung Cancer McDoniels -Silvers et al. 143
expression arrays (Clontech Laboratories, Palo Alto, CA) for
16 to 20 hours at 428C. Membranes were then washed twice,
each for 10 minutes in 2SSC, 0.1% SDS at room temper-
ature, and twice, each for 30 minutes in 0.1SSC, 0.1% SDS
at 558C, followed by exposure to Molecular Dynamics
Phosphorimager screens (Sunnyvale, CA) overnight. Densi-
tometry was performed using ImageQuant software.
Reverse Transcription PCR
Primers for each differentially expressed gene were
designed and ordered from Gibco BRL Life Technologies.
Each primer was diluted to 1 OD/100 L and forward
primers were then end- labeled with [ - 32P]dATP using
T4 polynucleotide kinase (New England Biolabs, Beverly,
MA). A total of 4 g normal / tumor tissue total RNA and
2.5 g oligo-dT primer were denatured at 658C for
10 minutes and placed on ice. To this mixture the following
components were added: 1reverse transcription buffer
(50 mM Tris–HCl, pH 8.3; 75 mM KCl; 3 mM MgCl2);
10 mM DTT; 1.0 mM of each dATP, dTTP, and dGTP;
100 Ci [ -32P]dCTP or 1.0 mM dCTP; 60 U RNAsin
(Promega); and 800 U MMLV reverse transcriptase (Gibco
BRL Life Technologies). Reaction mixtures were incubated
at 378C for 1 hour. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control in each
PCR amplification. The coamplification of the control cDNA
and the target gene cDNA in tumor and normal tissues
provided a means to control for PCR amplification and
enabled the relative level of the target gene expression
to be quantified. PCR reactions using 1 L cDNA,
1reaction buffer, 2 mM MgCl2, 0.2 mM dNTPs, 0.75 units
of Taq DNA Polymerase (Promega), labeled forward
primers, and unlabeled reverse primers were subjected to
18 to 24 cycles of amplification at 958C for 1 minute, 558C
for 1 minute, and 728C for 1 minute per cycle. To determine
the linear range of each set of PCR reactions, a series of 3
to 4 PCR reactions using 18, 20, 22, or 24 cycles were
performed for each target gene, and one of the reactions
that fitted into the linear range was used for further
quantitation. PCR products were then electrophoresed on
Table 2. Differentially Expressed Genes in Adenocarcinomas and Squamous Cell Carcinomas.
No. Gene GenBank No. RT RT Frequency
Oncogenes, tumor supressor genes, and cell cycle regulators
1 protein tyrosine kinase c - kit X06182  5 /7S, 6 / 7A, 1S&1A( + )
2 c - jun J04111  2 /7S, 5 / 7A
3 protein tyrosine kinase receptor tyro3 D17517  5 /7S, 5 / 7A
4 c - src K03214  5 /7S, 3 / 7A, 4S( + )
5 c - fgr proto - oncogene M19722  5 /7S, 4 / 7A, 1A( + )
6 TR3 orphan receptor L13740  6 /7S, 6 / 7A, 1S( + )
7 cdc25A M81933 + 5 /7S, 3 / 7A, 2A(  )
Stress response and modulators, effectors, and intracellular transducers
8 ephrin type -A receptor 1 M18391 + 3 /7S, 6 / 7A, 1S&2A(  )
9 LIM domain kinase 1 (LIMK -1 ) D26309 + 3 /7S, 4 / 7A, 1S(  )
10 ras - related protein RAB6 M28212 + 3 /7S, 3 / 7A, 1S(  )
11 ras - related protein RAB2 M28213 + 0S, 5 / 7A
12 janus kinase 3 ( JAK3 ) U09607 + 4 /7S, 3 / 7A, 1S&2A(  )
13 c - jun N - terminal kinase1 ( JNK1 ) L26318 + 4 /7S, 3 / 7A, 1S(  )
14 ephrin A3 (EFNA3 ) U14187 + 7 /7S, 6 / 7A
15 transmembrane receptor PTK7 U40271 + 3 /7S, 5 / 7A, 1S(  )
Apoptosis and DNA synthesis, repair, and recombination
16 adenosine A1 receptor (ADORA1) S56143  5 /7S, 3 / 7A, 2S( + )
17 caspase 8 U60520  3 /7S, 4 / 7A, 3A( + )
Receptors, cell surface antigens, and cell adhesion
18 insulin receptor ( INSR) M10051 + 3 /7S, 4 / 7A, 2S(  )
19 IL2R X01057 + 4 /7S, 7 / 7A
20 CD27L antigen receptor M63928 + 5 /7S, 5 / 7A
21 ICAM1 J03132  7 /7S, 2 / 7A, 1S&1A( + )
Growth factors, cytokines, chemokines, and interferons
22 HGF activator D14012 + 4 /7S, 6 / 7A, 2S&1A(  )
23 AR M30704  6 /7S, 5 / 7A, 2A( + )
24 vascular endothelial growth factor C U43142  4 /7S, 2 / 7A, 1S&1A( + )
25 platelet - derived growth factor A (PDGFA ) X06374 + 4 /7S, 4 / 7A, 2S&1A(  )
26 macrophage inflammatory protein 2 alpha X53799  5 /7S, 6 / 7A
A, adenocarcinoma. S, squamous cell carcinoma.  , underexpressed; + , overexpressed compared to normal lung tissue from the same patient. RT, reverse
transcription–PCR analysis.
RT Frequency, ratio of the number of tumors with differential expression over the total number of normal / tumor tissue pairs analyzed; S /A( + /  ), differential
expression detected in tumors that did not reflect what was found in the majority of normal / tumor tissue pairs.
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Figure 2. Differential expression of c - jun. (A ) cDNA expression array hybridization with the squamous cell carcinoma 8706 and its matching normal tissue and the
adenocarcinoma 94 -11 -C066R (66R ) and its matching normal tissue 94 -11 -C065R (65R ). (B ) RT -PCR confirmation. The first two pairs of tumor / normal tissues
from the left are squamous cell carcinomas of the lung. The remaining three pairs of tumor / normal tissues are lung adenocarcinomas.
Figure 3. Differential expression of AR. (A ) cDNA expression array hybridization with the squamous cell carcinoma 8706 and its matching normal tissue and the
adenocarcinoma 94 -11 -C066R (66R ) and its matching normal tissue 94 -11 -C065R (65R ). (B ) RT -PCR confirmation. The first two pairs of tumor / normal tissues
from the left are squamous cell carcinomas of the lung. The remaining three pairs of tumor / normal tissues are lung adenocarcinomas.
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8% polyacrylamide gels with urea and exposed to
Molecular Dynamics Phosphorimager screens for analysis.
Densitometry was performed by ImageQuant software.
Results
The 588 human cDNAs immobilized on each Atlas human
cDNA expression array consisted of 200 to 600 base pair
fragments amplified from mRNA regions without polyA tails,
highly homologous sequences, or base sequence repeats.
This ensured that nonspecific background and cross hybrid-
ization of closely related gene family members was
minimized. The low background levels acquired from use
of primers specific for the genes immobilized on the nylon
membrane allowed for the detection of mRNAs as rare as 10
to 20 copies per cell [26]. The cDNA spot signal intensity
was compared to three housekeeping gene spot signal
intensities (GAPDH,  -actin, and 60S ribosomal RNA gene)
to determine the relative abundance of target cDNA in the
hybridized sample.
Six different sets of cDNAs were immobilized on cDNA
expression arrays at approximately 10 ng per spot includ-
ing: 1) oncogenes, tumor suppressor genes, and cell cycle
regulators; 2) ion channel and transport, stress response,
and modulators, effectors, and intracellular transducer
genes; 3) genes involved in apoptosis, DNA synthesis,
repair and recombination; 4) transcription factors and DNA
binding proteins; 5) receptors, cell surface antigens, and
cell adhesion molecules; 6) growth factors, cytokines,
chemokines, hormones, interleukins, and interferons [26].
Using the Altas human cDNA expression array, four sets
of hybridizations were performed with reverse- transcribed
polyA+ RNA of two squamous cell carcinomas and their
matching normal tissues (patients 8611 and 8706) and two
adenocarcinomas and their matching normal tissues
(patients 8641 and 94-11-C066/65R). Representative
examples of the pathologic features of an adenocarcinoma
and its paired normal alveoli as well as a squamous cell
carcinoma and its paired normal bronchiole are shown in
Figure 1.
Of the 588 cDNAs present on the cDNA expression array,
an average of 262 spots (45%) were detected after hybrid-
ization. After normalization to housekeeping genes GAPDH,
 -actin, and 60S ribosomal protein L13A, sequences that
were differentially expressed by at least two- fold between
tumor and normal tissues were selected for further con-
firmation. Because each housekeeping gene standardized
the cDNA spot intensities to different relative levels, only
those cDNAs that were differentially expressed by at least
two- fold when normalized to each of these housekeeping
genes were examined further. The two- fold expression
differences also needed to be detected in at least two of the
Figure 4. Differential expression of IL - 2R. (A ) cDNA expression array hybridization with the squamous cell carcinoma 8706 and its matching normal tissue and the
adenocarcinoma 94 -11 -C066R (66R ) and its matching normal tissue 94 -11 -C065R (65R ). (B ) RT -PCR confirmation. The first two pairs of tumor / normal tissues
from the left are squamous cell carcinomas of the lung. The remaining three pairs of tumor / normal tissues are lung adenocarcinomas.
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four individual hybridizations that were performed, with two
expression differences occurring in the same lung cancer
subtype. Forty- five genes (17%) were differentially
expressed in the cDNA expression array screening and
selected for reverse- transcriptase polymerase chain reac-
tion (RT-PCR) confirmation. Of these, 22 were overex-
pressed and 23 were underexpressed in the tumor tissues
compared to their normal counterparts. The initial RT-PCR
analysis was performed using seven pairs of matching
normal / tumor tissues ( three squamous cell carcinomas and
four adenocarcinomas). Only the genes that displayed
differential expression in >50% of the squamous cell
carcinomas and/or adenocarcinomas were reanalyzed
using the second set of seven matching normal / tumor
tissues ( four squamous cell carcinomas and three adeno-
carcinomas). Final analysis included 26 of the initial 45
genes (58%) that were differentially expressed by cDNA
expression array analysis.
Of the 26 genes, 14 genes were overexpressed and
12 genes were underexpressed in the tumor tissues
compared to their corresponding normal tissues (Table 2).
Most of the differentially expressed genes were detected in
both squamous cell carcinomas and adenocarcinomas.
Eight genes were overexpressed or underexpressed in at
least 70% of adenocarcinomas and squamous cell carcino-
mas. Of these, two were overexpressed (CD27L antigen
receptor and ephrin A3) whereas six were underexpressed
(c-kit, protein tyrosine kinase receptor tyro3, c- fgr proto-
oncogene, TR3 orphan receptor, amphiregulin (AR), and
macrophage inflammatory protein 2 alpha). However, some
expression differences were more common in adenocarci-
nomas (c- jun, ephrin type A receptor 1, and interleukin
2 receptor alpha [ IL2R ] ). Differential expression of
intercellular adhesion molecule 1 ( ICAM1) was more
frequently detected in squamous cell carcinomas. The ras-
related gene, rab2, was only differentially expressed in
adenocarcinomas. Some genes were overexpressed in one
NSCLC subtype but were variable or underexpressed in the
other subtype. Cdc25A was overexpressed by at least two-
fold in some squamous cell carcinomas but underexpressed
in some adenocarcinomas compared to their respective
normal tissues. Caspase 8 and insulin receptor were
overexpressed in most adenocarcinomas but underex-
pressed in squamous cell carcinomas. Because sample
sizes were small, more NSCLC subtypes need to be
analyzed to substantiate these tendencies. Figures 2 4
show the representative results of differential expression of
c- jun, AR, and IL2R. Further verification of differential gene
expression in either squamous cell carcinomas or adeno-
carcinomas by Northern blot analysis could not be performed
due to the limited amount of microdissected tumor tissues
available for the present study.
Discussion
In this study, we compared the gene expression patterns of
two subtypes of human NSCLC, adenocarcinomas and
squamous cell carcinomas, to their matching normal lung
tissues using Atlas human cDNA expression arrays. The use
of this limited cDNA microarray with known genes, which
were potentially related to cancer, certainly enriched for
genes that might appear to be related directly to the cancer
process. Approximately half of the 588 spotted cDNAs were
detected in these normal and tumor tissues. Forty- five of the
262 cDNAs were differentially expressed according to the
parameters set at the beginning of the study and were
selected for further RT-PCR confirmation. Twenty-six
genes including oncogenes, cell cycle regulators, intra-
cellular signal transducers, apoptotic genes, cell receptors
and adhesion molecules, and growth factors were differ-
entially expressed in adenocarcinomas and/or squamous
cell carcinomas compared to normal lung tissues obtained
from the same patient. We found eight genes that were
reproducibly (>70% of samples) altered in both adenocarci-
nomas and squamous cell carcinomas when compared with
their normal controls. In general, the expression of genes
identified in both adenocarcinomas and squamous cell
carcinomas were routinely increased or decreased by more
than two- fold.
Proto-oncogenes
Several members of this group were routinely altered in
expression in both adenocarcinomas and squamous cell
carcinomas. Interestingly, most of the genes with aberrant
expression had decreased expression relative to their own
controls including c-kit, c- fgr, c-src, and c- jun. c-Kit
encodes a transmembrane tyrosine kinase receptor. It
functions in cell survival, proliferation, migration, and
differentiation [27]. The c-kit and stem cell factor (SCF)
autocrine loop in SCLC may mediate chemotaxis and/or
provide a growth advantage in these tumors [28,29].
Chemotactic and chemokinetic mobility was detected in
lung cancer cell lines expressing c-kit and SCF [30].
Tonary et al. reported that c-kit expression was decreased
in advanced stages of ovarian cancer and was associated
with decreased survival [31].
Non–receptor tyrosine kinase, c-src, has been implicated
in the tumorigenesis of multiple human cancers. Reported
alterations involved both increases and decreases in
enzymatic activity, gene copy number, and protein levels
[32]. In lung cancer, elevated c-src expression was found in
60% of tumors of different histologic types, including
adenocarcinomas and squamous cell carcinomas, com-
pared to normal bronchial tissue [33,34]. Budde et al.
reported high c-src activity for NSCLC cell lines but low
activity in SCLC cell lines [35]. In our study, c-src levels
were elevated in the majority of squamous cell carcinomas
but were decreased in three of seven adenocarcinomas.
This may suggest different functional roles for this proto-
oncogene in these NSCLC subtypes.
c-Jun is a tightly regulated component of the activator
protein-1 transcription factor complex. It is involved in cell
proliferation and survival but can also induce apoptosis,
growth arrest, and differentiation [36]. Expression analysis
of c- jun in lung cancer has yielded conflicting results.
Koomagi et al. reported elevated levels of c- jun in tumor
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tissues of lung cancer patients compared to adjacent normal
tissues [37]. However, in an additional study comparing 101
NSCLC specimens to adjacent normal lung tissue, 72% of
the normal tissues expressed higher levels of c- jun [38]. In
light of these observations, additional studies will need to be
performed to define the role of c-kit, c - fgr, c -src, and c- jun
in tumorigenesis.
Growth Factors and Related Genes
Several growth factors and related genes were also
expressed differentially in the NSCLC subtypes compared
to normal lung tissues. Hepatocyte growth factor (HGF) is
a potent inducer of cell proliferation, motility, and morpho-
genesis [39]. A probable autocrine loop involving HGF and
its receptor c-met exists in NSCLC [6,40]. HGF is
secreted in an inactive form and must be proteolytically
activated by factors such as HGF activator (HGFA) [41].
Although HGFA levels have not been examined in many
tissues ( including lung), significantly higher HGFA levels
were reported in breast cancer tissue than in normal
control tissues [39]. Increased HGFA expression was
found in two of seven squamous cell carcinomas and five
of seven adenocarcinomas.
Another differentially expressed gene in this study was
AR. It is a strong growth promoter for breast, colon, lung, and
ovarian epithelial cells and may function in autocrine and
paracrine loops with the epidermal growth factor receptor
(EGFR) to promote tumorigenesis [42,43]. However, it has
also been reported to inhibit growth of carcinoma cell lines
[44,45]. Both reduced (63%) and increased (11%) AR
expression levels have been reported in NSCLC tumors
compared to uninvolved lung tissue [46]. Most of the NSCLC
samples in our study exhibited reduced AR expression
compared to normal lung tissue. Only two of seven (28%)
adenocarcinomas showed increased expression of AR
compared to normal lung counterparts.
Intracellular Signal Transducers
Several modulators, effectors, and intracellular trans-
ducers showed increased expression in the human lung
tumors. The receptor tyrosine kinase erythropoietin-produc-
ing hepatocellular (eph) family transduces signals to
proteins involved in cytoskeletal organization, adhesion,
migration, and proliferation [47,48] and may also be involved
in angiogenesis [49-51]. Overexpression of eph receptors
has been detected in gastric carcinomas, malignant mela-
nomas, and hepatomas [52]. Overexpression of ephA1
receptor was able to transform NIH3T3 cells [48]. We found
frequent overexpression of both ephA1 receptor and ephrin
A3 ligand in both squamous cell carcinomas and adenocar-
cinomas compared to matching normal tissues.
LIM domain kinase (LIMK-1) is a serine/ threonine kinase
involved in the Rho GTPase signaling pathway that leads to
actin cytoskeleton reorganization and the formation of
lamellipodia [53-55]. Although LIMK-1 has not previously
been implicated in cancer, it was overexpressed in two of
seven squamous cell carcinomas and four of seven
adenocarcinomas in this study.
Apoptotic Factors
Another component of neoplastic transformation is the
prevention of apoptosis. Death receptor–dependent and –
independent activation of caspase 8 leads to cleavage and
activation of effector caspases 3, 6, and 7 and other
intermediate apoptotic signaling proteins [56,57] that then
initiate cell death. In neuroblastoma, caspase 8 was often
inactivated by gene deletion and/or DNA methylation in cells
with N-myc amplification [58]. However, in several other
cancers including high-grade non-Hodgkins lymphoma,
breast carcinoma, pancreatic carcinoma, and gallbladder
carcinoma, caspase 8 gene expression was upregulated
[59-62] and was strongly associated with the extent of
apoptosis [58,60,62]. In this study, caspase 8 was down-
regulated in several squamous cell carcinomas (3/7) but
primarily upregulated in adenocarcinomas (3/7).
Using the rapid, high- throughput human Atlas cDNA
expression array system, we examined the gene expres-
sion profiles of 14 NSCLCs and their matching normal
tissues. Numerous cell surface receptors, proto-onco-
genes, growth factors, and signal transduction molecules
were differentially expressed in these NSCLC subtypes
and may have significant roles in lung tumorigenesis. The
divergent expression patterns of c-src, caspase 8, cdc25A,
rab2, and ICAM1 (see Table 2) suggest subtle but
probable molecular differences between human lung
adenocarcinomas and squamous cell carcinomas. These
differences may ultimately play a role in determining the
best treatments for these two NSCLC subtypes. Differential
gene expression in tumor and normal lung tissues does not
necessarily suggest tumor promoter or tumor inhibitory
function. These differences may be a consequence of
other biochemical changes that occur in a cell on its path
to neoplastic transformation. Nevertheless, the changes in
gene expression may serve as diagnostic or prognostic
tumor biomarkers. Others may prove to be modulated by
therapeutic or preventative agents and, thus, serve as
surrogate endpoint biomarkers.
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